Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China
· Delayed Price · Currency is CNY 20.42
+0.41 (2.05%)
Mar 10, 2026, 11:30 AM CST
Nanjing Vazyme Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Net Income | - | -18.09 | -70.96 | 594.25 | 678.29 | Upgrade
|
| Depreciation & Amortization | - | 138.01 | 157.38 | 122.1 | 55.28 | Upgrade
|
| Other Amortization | - | 75.31 | 78.26 | 94.83 | 27.92 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 2.1 | -5.67 | 0.22 | -0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 1.8 | 1.73 | 236.85 | 2.35 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -59.9 | -50.92 | -88.02 | -29.81 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 20.26 | -7.27 | 91.68 | 12.08 | Upgrade
|
| Other Operating Activities | - | 57.09 | 165.4 | 333.07 | 46.61 | Upgrade
|
| Change in Accounts Receivable | - | -188.25 | 534.67 | -682.89 | -133.2 | Upgrade
|
| Change in Inventory | - | -39.04 | -124.37 | -403.82 | -148.94 | Upgrade
|
| Change in Accounts Payable | - | -13 | -511.13 | 464.58 | 113.78 | Upgrade
|
| Change in Other Net Operating Assets | - | 53.56 | 25.28 | 7.37 | 7.47 | Upgrade
|
| Operating Cash Flow | - | -9.68 | 152.99 | 735.17 | 616.8 | Upgrade
|
| Operating Cash Flow Growth | - | - | -79.19% | 19.19% | -23.24% | Upgrade
|
| Capital Expenditures | - | -74.9 | -232.9 | -962.86 | -261.96 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 2.47 | 13.48 | 15.59 | 2.73 | Upgrade
|
| Cash Acquisitions | - | - | - | -117.93 | - | Upgrade
|
| Investment in Securities | - | 395.03 | -726.65 | 51.07 | -1,195 | Upgrade
|
| Other Investing Activities | - | 52.6 | 45.42 | 61.7 | 26.15 | Upgrade
|
| Investing Cash Flow | - | 375.21 | -900.65 | -952.44 | -1,428 | Upgrade
|
| Short-Term Debt Issued | - | 1,105 | 1,461 | 372 | - | Upgrade
|
| Long-Term Debt Issued | - | 0.02 | 0.56 | - | - | Upgrade
|
| Total Debt Issued | - | 1,105 | 1,462 | 372 | - | Upgrade
|
| Short-Term Debt Repaid | - | -1,723 | -638.79 | -156.41 | -39.56 | Upgrade
|
| Total Debt Repaid | - | -1,723 | -638.79 | -156.41 | -39.56 | Upgrade
|
| Net Debt Issued (Repaid) | - | -618.8 | 822.77 | 215.59 | -39.56 | Upgrade
|
| Issuance of Common Stock | - | 38.5 | - | - | 2,129 | Upgrade
|
| Repurchase of Common Stock | - | -104.4 | -20.01 | - | - | Upgrade
|
| Common Dividends Paid | - | -80.36 | -533.33 | -132.24 | -4.45 | Upgrade
|
| Other Financing Activities | - | -21.21 | -19.63 | -4.3 | -15.2 | Upgrade
|
| Financing Cash Flow | - | -786.27 | 249.8 | 79.05 | 2,070 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -4.24 | 1.46 | 5.04 | -2.32 | Upgrade
|
| Net Cash Flow | - | -424.98 | -496.4 | -133.18 | 1,256 | Upgrade
|
| Free Cash Flow | - | -84.58 | -79.91 | -227.69 | 354.84 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -45.49% | Upgrade
|
| Free Cash Flow Margin | - | -6.14% | -6.21% | -6.38% | 18.99% | Upgrade
|
| Free Cash Flow Per Share | - | -0.23 | -0.20 | -0.57 | 0.98 | Upgrade
|
| Cash Income Tax Paid | - | 61.14 | 99.76 | 146.72 | 175.67 | Upgrade
|
| Levered Free Cash Flow | - | -105.83 | -102.16 | -451.34 | 181.59 | Upgrade
|
| Unlevered Free Cash Flow | - | -88.79 | -80.25 | -443.54 | 184 | Upgrade
|
| Change in Working Capital | - | -226.25 | -114.95 | -649.81 | -175.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.